Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Total Debt (2023 - 2025)

Telix Pharmaceuticals has reported Total Debt over the past 3 years, most recently at $405.0 million for Q4 2025.

  • Quarterly Total Debt rose 8.5% to $405.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $405.0 million through Dec 2025, up 8.5% year-over-year, with the annual reading at $405.0 million for FY2025, 8.5% up from the prior year.
  • Total Debt was $405.0 million for Q4 2025 at Telix Pharmaceuticals, up from $373.3 million in the prior quarter.
  • Over five years, Total Debt peaked at $405.0 million in Q4 2025 and troughed at $6.0 million in Q4 2023.
  • The 3-year median for Total Debt is $373.3 million (2024), against an average of $261.4 million.
  • Year-over-year, Total Debt soared 6151.08% in 2024 and then rose 8.5% in 2025.
  • A 3-year view of Total Debt shows it stood at $6.0 million in 2023, then soared by 6151.08% to $373.3 million in 2024, then grew by 8.5% to $405.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Total Debt are $405.0 million (Q4 2025), $373.3 million (Q4 2024), and $6.0 million (Q4 2023).